Technology | November 05, 2012

Elekta Introduces Mosaiq Connectivity for its microSelectron Digital Brachytherapy Afterloader

Oct. 29, 2012 - At the 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO, Boston, Mass.), Elekta announced that MOSAIQ Oncology Information System (OIS) v 2.50 now includes connectivity with Nucletron's microSelectron® Digital afterloader. This added connectivity allows the treatment record and chart information, in addition to dose and structure sets, to be part of the complete patient record – saving time, simplifying workflow and creating a paperless flow of brachytherapy practice information.

MOSAIQ-microSelectron Digital connectivity is the latest in Elekta's long history of providing interfaces with virtually any radiotherapy delivery device or treatment planning system.

MOSAIQ now integrates with Accuray CyberKnife system 
Recently, St. Anthony Hospital (Oklahoma City, Okla.) became the first center to use a MOSAIQ interface for its Accuray CyberKnife radiosurgery system. A MOSAIQ user for several years, St. Anthony officials had discussed the possibility of a MOSAIQ interface for CyberKnife with Accuray representatives.

"We are always trying to pursue opportunities to improve the communication capabilities of our interfaces," says Chad Crane, BSRT(T), St. Anthony Supervisor, Radiation Oncology. "Since MOSAIQ is our primary department EMR, to have that functionality added to it was something we wanted to participate in."

According to St. Anthony Lead Physicist, Cindy Parry, M.S., the MOSAIQ-CyberKnife interface presented an opportunity to streamline their radiosurgery process and to consolidate all patient information in a single location.

"To me, the greatest value is that the treatment is directly transferred to MOSAIQ through the interface," she adds. "In this way, the physician seeing a patient for follow up can readily note that a CyberKnife patient got his fractions done in x amount of time, or can see if this patient also had an HDR or linac treatment – all that information will be in the patient record for him to see at once."

Mevion proton delivery added to MOSAIQ connectivity portfolio
Elekta also reported in October that MOSAIQ now includes interconnectivity with Mevion Medical Systems' MEVION S250 proton therapy system.

"The integration of the MEVION S250 with MOSAIQ is another important step toward making proton therapy accessible to more patients," says Lionel G. Bouchet, Ph.D., Senior Director Product Management, Mevion Medical Systems.

More than 20 years of open-vendor connectivity
With a longstanding open-systems development philosophy, MOSAIQ includes interfaces to Elekta's portfolio of linear accelerators, Elekta's Leksell Gamma Knife® Perfexion, and a broad array of third-party delivery systems, including Varian's TrueBeam, Accuray's TomoTherapy system, and Siemens' Artiste and ONCOR systems, in addition to many other commercially available radiotherapy systems.

"With the latest additions to the MOSAIQ interface portfolio, Elekta maintains its ongoing commitment to develop seamless MOSAIQ connectivity for any treatment system or treatment planning system," says Todd Powell, Executive Vice President, Elekta Software. "We match this effort with our constant introduction of new and clinically useful MOSAIQ functionality that health care providers can harness to improve the patient experience."

More than 2,500 global customers count on Elekta software to help them provide the safest and most efficient treatments in the fight against cancer. From its multiple redundant safety features to industry-leading practice management capabilities, MOSAIQ is the tool of choice to manage cutting-edge treatment centers.

For more information: www.elekta.com

Related Content

Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
University of Wisconsin-Madison Partners With RaySearch on RayCare OIS
News | Oncology Information Management Systems (OIMS) | June 21, 2017
The Department of Human Oncology at the University of Wisconsin-Madison has entered into an agreement with RaySearch to...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Versa

Image courtesy of Elekta

News | Radiation Therapy | June 13, 2017
Radiation therapy (RT) using high-energy particles, like X-rays or electron beams, is a common and critical component...
News | Radiation Oncology | June 12, 2017
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Overlay Init